undamentalytics Newsletter

Fmr LLC: insider trades

10% owner, Other at 8 companies we cover. 1 open-market purchase and 44 sales not made under a pre-set plan, reported from July 11, 2012 to June 29, 2026.

Would copying Fmr LLC’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 1 purchase has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on July 7, 2014 into $10,201 by November 2, 2026, +0.2% a year. The copy held shares only 8% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $13,880, +2.7% a year (the S&P 500 held throughout made $46,959, +13.4% a year). Beta against the index was 0.04. Twelve months after each report, the average purchase was −28.5% against the S&P 500 (median −28.5%), and 0% beat it. Measured from the trade date, the insider’s own timing, the average was −23.0%. After their sales, the shares moved +10.0% against the index over 12 months on average (a negative figure means selling was the right call); 48% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 2014201620182020202220242026 $47.0k$13.9k$10.2k
Copying Fmr LLCS&P 500, same days investedS&P 500, held throughout $10,000 copying Fmr LLC’s open-market purchases from July 7, 2014, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+0.2%
S&P 500, same days invested
+2.7% (held throughout +13.4%)
Time in shares
8%
Sharpe ratio (S&P 500)
−0.21 (0.69)
Biggest drop (S&P 500)
−27% (−34%)
Market sensitivity (beta)
0.04
Purchases copied
1

Trade by trade

Fmr LLC: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 1 −11.5% −11.5% 0% 1 — — Not enough years
Purchases, 6 months after the report 1 −4.2% −4.2% 0% 1 — — Not enough years
Purchases, 12 months after the report 1 −28.5% −28.5% 0% 1 — — Not enough years
Purchases, 12 months after the trade 1 −23.0% −23.0% 0% 1 — — Not enough years
Sales, 3 months after the report 43 −5.0% −10.4% 67% 7 −0.77 0.47 No reliable evidence
Sales, 12 months after the report 42 +10.0% +23.0% 48% 6 −0.39 0.71 No reliable evidence
Sales, 12 months after the trade 42 +10.6% +17.7% 48% 6 −0.38 0.72 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Regenxbio Inc. RGNX —014April 15, 2016May 18, 2016
Ironwood Pharmaceuticals Inc IRWD —010July 11, 2012October 9, 2012
Insmed Inc INSM —09June 6, 2013July 23, 2013
Beam Therapeutics Inc. BEAM —07April 14, 2022June 29, 2026
Coherus Oncology, Inc. CHRS —02August 8, 2016August 10, 2016
Generac GNRC —10July 3, 2014July 3, 2014
Aclaris Therapeutics, Inc. ACRS —01October 28, 2016October 28, 2016
Sana Biotechnology, Inc. SANA —01January 10, 2025January 10, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
June 29, 2026June 25, 2026 BEAM Sale $10,039,492 −31.1%not yetnot yet
October 29, 2025October 27, 2025 BEAM Sale $12,246 +14.7%−3.8%−6.3%
August 1, 2025July 30, 2025 BEAM Sale $991,667 +22.4%+18.3%+7.6%
January 10, 2025January 8, 2025 SANA Sale $1,887,320 not yetnot yetnot yet
February 15, 2024February 13, 2024 BEAM Sale $27,545,051 −31.5%−23.0%−16.9%
September 8, 2022September 6, 2022 BEAM Sale $29,892 −20.1%−66.0%−68.2%
August 8, 2022August 5, 2022 BEAM Sale $1,229,806 −30.6%−68.5%−68.9%
April 14, 2022April 13, 2022 BEAM Sale $981,205 +57.0%−24.7%−33.1%
October 28, 2016October 26, 2016 ACRS Sale $82,260 +16.3%−4.8%−12.4%
August 10, 2016August 8, 2016 CHRS Sale $2,986,216 −9.3%−75.1%−70.8%
August 8, 2016August 4, 2016 CHRS Sale $1,383,988 −12.0%−73.2%−71.4%
May 18, 2016May 17, 2016 RGNX Sale $227,103 −6.2%+32.3%+28.7%
May 17, 2016May 13, 2016 RGNX Sale $186,765 −8.3%+37.6%+50.0%
May 13, 2016May 12, 2016 RGNX Sale $72,833 −6.0%+38.4%+49.8%
May 12, 2016May 10, 2016 RGNX Sale $260,453 −5.8%+50.0%+56.4%
May 10, 2016May 6, 2016 RGNX Sale $105,087 −19.6%+42.9%+64.0%
May 6, 2016May 4, 2016 RGNX Sale $19,919 −10.6%+72.9%+62.4%
May 4, 2016May 2, 2016 RGNX Sale $65,066 −20.7%+66.2%+72.1%
May 2, 2016April 29, 2016 RGNX Sale $51,020 −28.3%+60.5%+95.5%
April 29, 2016April 27, 2016 RGNX Sale $372,703 −28.7%+72.1%+68.9%
April 27, 2016April 25, 2016 RGNX Sale $102,832 −31.4%+69.0%+66.0%
April 25, 2016April 21, 2016 RGNX Sale $232,241 −34.5%+71.5%+67.1%
April 21, 2016April 19, 2016 RGNX Sale $153,765 −34.3%+74.8%+62.9%
April 19, 2016April 15, 2016 RGNX Sale $222,132 −37.8%+66.5%+65.1%
April 15, 2016April 12, 2016 RGNX Sale $309,907 −40.0%+60.6%+38.7%
July 3, 2014July 1, 2014 GNRC Purchase $1,277,983 −11.5%−28.5%−23.0%
July 23, 2013July 19, 2013 INSM Sale $1,909,360 +18.8%+35.0%+27.9%
July 18, 2013July 16, 2013 INSM Sale $3,565,034 +30.2%+27.9%+44.7%
July 15, 2013July 11, 2013 INSM Sale $1,744,007 +18.5%+44.7%+57.1%
July 9, 2013July 5, 2013 INSM Sale $1,467,742 +26.6%+51.6%+64.1%
July 3, 2013July 1, 2013 INSM Sale $3,644,585 +47.7%+64.1%+81.7%
June 26, 2013June 24, 2013 INSM Sale $600,000 +23.1%+42.2%+27.8%
June 21, 2013June 19, 2013 INSM Sale $1,751,307 +12.5%+27.8%+31.1%
June 13, 2013June 11, 2013 INSM Sale $1,115,095 +23.8%−20.3%−19.7%
June 6, 2013June 4, 2013 INSM Sale $1,678,213 +15.8%−21.3%−27.7%
October 9, 2012October 4, 2012 IRWD Sale $251,220 +14.1%−36.7%−30.4%
September 28, 2012September 26, 2012 IRWD Sale $1,251,719 −10.4%−28.4%−30.5%
September 20, 2012September 18, 2012 IRWD Sale $2,143,364 −22.9%−36.9%−30.7%
September 4, 2012August 30, 2012 IRWD Sale $317,156 −10.9%−14.0%−22.6%
August 1, 2012July 30, 2012 IRWD Sale $97,812 −11.1%−30.3%−27.3%
July 30, 2012July 25, 2012 IRWD Sale $782,387 −12.8%−29.1%−34.3%
July 24, 2012July 20, 2012 IRWD Sale $299,572 −10.9%−34.3%−38.6%
July 20, 2012July 17, 2012 IRWD Sale $980,536 −8.7%−31.6%−42.1%
July 16, 2012July 12, 2012 IRWD Sale $486,637 −6.7%−42.1%−44.3%
July 11, 2012July 9, 2012 IRWD Sale $261,451 −15.3%−44.3%−50.1%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Fmr LLC traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.